Clinical Research Directory
Browse clinical research sites, groups, and studies.
Aciclovir Versus Placebo for HSV-2 Meningitis
Sponsor: Jacob Bodilsen
Summary
To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation
Official title: Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-06-01
Completion Date
2029-06-01
Last Updated
2025-10-01
Healthy Volunteers
Yes
Conditions
Interventions
Acyclovir 50 MG/ML
Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
Placebo
Placebo either in IV formulation or as tablets identical to valacyclovir tablets.